ClinicalTrials.gg
TerminatedNCT03033316AMETHYSTUpdated Nov 6, 2020

A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma

A Phase 1/2 interventional study of Dexamethasone in Multiple Myeloma, sponsored by Enceladus Pharmaceuticals BV. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-06.

Sponsored by Enceladus Pharmaceuticals BV · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Patient enrolment issues

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
331st of 373
7 · median 45
Started
2017
with 21 others
Phase 1/2
52 of 381
11 open now
Registered
224th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 331st largest by enrollment of the 373 interventional ones that give a count, is one of 22 that started in 2017, is one of 52 in phase 1/2, and was the 224th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged lesion uptake of dexamethasone and therefore increased therapeutic benefit over existing formulations of dexamethasone in Multiple Myeloma. The current trial is a first-in-man study with Oncocort monotherapy with the objective to assess safety, tolerability, efficacy and dose response after short-term treatment with repeated infusions.

Read the detailed description

This open label multicenter study will evaluate the safety and efficacy of I.V. Oncocort Dexamethasone sodium phosphate given as a short term induction therapy in Multiple Myeloma patients. It consist of a Phase 1 part with a maximum number of 5 ascending dose levels while additional patients will be treated in the Phase 2a part with the recommended phase 2 dose to obtain additional safety data and preliminary efficacy data in multiple myeloma patients. For the dose escalation phase 1 part, 3 patients per dose level will be enrolled. If one patient reaches DLT, another 3 patients will be enrolled in the same dose level. If two or more patients reach DLT in one dose level, maximum tolerated dose (MTD) is defined at the last dose level beneath DLT. Not more than 5 dose level groups are anticipated for this part of the study. MTD will be the Recommended Phase II Dose (RPTD) for the phase IIa part of the study. For the phase 2a part, 7 additional patients will be enrolled at the RPTD dose level, bringing the total number of patients monitored for responses at this dose level to at least 10.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Liposomal Dexamethasone
  • Targeted Drug Delivery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously diagnosed symptomatic MM according to International Myeloma Working Group (IMWG) criteria 1.1. Previously treated with at least two therapy lines including at least one proteasome-inhibitor and at least one immunomodulatory drug 1.2. Relapse after or progressive disease under last therapy according to IMWG criteria.
  2. At least 18 years old
  3. (M-protein and/or free light chains) in serum and/or urine
  4. Willing and able to comply the study protocol visits and assessments
  5. Willing to use highly effective methods of (see section 7.1.3)
  6. Written prior to study participation

Exclusion criteria

Exclusion Criteria:

  1. Types of Multiple Myeloma previously shown to be irresponsive to dexamethasone monotherapy during the last 6 months
  2. Plasma cell leukemia
  3. Subject with positive hepatitis panel (including surface antigen [HBsAg], and / or anti-hepatitis B core antibodies, and / or virus antibody [anti-HCV]), and / or a positive antibody screen
  4. Severe abnormal organ function function or laboratory results at the time of the Screening Visit: WBC \<3.0 g/L, ANC \<1.5 G/L, \<50 G/L, Sodium \<135 mmol/L or >150 mmol/L, potassium \<3.5 mmol/L or >5.5 mmol/L, calcium \<2.0 mmol/L or > 2.9mmol/L, phosphorus \<0.8 mmol/L, total >1.5x , AP >2.5x ULN, gammaGT >3x ULN, >3x ULN, CK >2.5x ULN, Creatinine >2x ULN, fasting glucose >250 mg/dL, albumin \<3 g/dL, cholesterol > 300 mg/dL
  5. Treatment with oral or injectable (including intra-articular) (CS) within 4 weeks prior to Screening Visit. Inhaled and dermal corticosteroid formulations are allowed
  6. Subjects who have received a chemotherapeutic treatment cycle including dexamethasone within 4 weeks prior to the Screening Visit
  7. Known sensitivity to any component of the study drug or previous reaction or other reaction to intravenous medications, biologic therapy or IV radiocontrast agents
  8. Active infection requiring systemic treatment
  9. Planned major surgery during the study period or had undergone major surgery within 30 days prior to the Screening visit
  10. Pregnancy or breastfeeding
  11. Any clinically significant hepatic, renal, cardiac, pulmonary, gastrointestinal, metabolic or endocrine disturbances, other medical or psychiatric condition, or clinically relevant abnormal values on any investigation, in the opinion of the Investigator, that could make the subject unsuitable for the study, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study, including severe neuropathies or other painful conditions that might interfere with pain evaluation
  12. Participation in another clinical investigation less than 4 weeks prior to inclusion
  13. The subject has a history of any other illness, which, in the opinion of the Investigator, might pose an unacceptable risk by administering study medication.
  14. The subject has any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study
  15. The subject is unwilling or unable to follow the procedures outlined in the protocol
  16. The subject is mentally or legally incapacitated
  17. Persons who are in a relationship of dependence to the Investigator or the Sponsor
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    IV Liposomal Dexamethasone

    IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks

    Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: Week 8

Secondary outcomes

  1. Response according to IMWG Criteria

    Time frame: 4 and 8 weeks after 1st dose

  2. Percentage change of myeloma-related measures

    Time frame: up to 8 weeks after 1st dose

  3. Quality of life questionnaire

    Time frame: up to 8 weeks after 1st dose

  4. Peak Plasma Concentration (Cmax)

    Time frame: during 1st 4 weeks

  5. Area under the plasma concentration versus time curve (AUC)

    Time frame: during 1st 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Aug 2020, 43 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2017
First posted
Jan 26, 2017
StartActual
Jan 2017
Primary completionActual
Aug 2020
CompletionActual
Aug 2020
Last update
Nov 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03033316
Lead sponsor
Enceladus Pharmaceuticals BV
Collaborators
University Hospital, Aachen, Accelovance
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Jan 2017
Primary completion
Aug 2020
Completion
Aug 2020
Last update
Nov 6, 2020

Study contacts

Stefan Wilop, MD
principal investigator · RWTH University Clinic Aachen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion